InvestSMART

Lynch Group Holdings Limited (ASX:LGL)

ALERT: Price-sensitive ASX Announcement for LGL
Current share price for LGL : $2.150 0.01 (0.47%)+
Announcement
Release
21 Nov 2025 9:23AM
Price at Release
$2.140
Full Release
download
Summary
The document details a scheme meeting presentation for Lynch Group Holdings Limited, where shareholders were asked to approve a scheme of arrangement for the acquisition of all issued share capital by Hasfarm Holdings Limited and Hasfarm Bidco Pty Ltd. The proposed scheme offers $2.155 cash per share, representing a significant premium over recent trading prices. The scheme has been approved by the requisite majorities of shareholders, with further approval needed from the court. The independent expert has advised that the scheme is fair, reasonable, and in the best interest of shareholders. Lynch directors unanimously support the scheme, and no superior proposal has been presented. The transaction involves estimated costs of $5 million, with $2.5 million as non-recoverable if the scheme doesn't proceed.
Key Points
  • Approval sought for a scheme of arrangement between Lynch Group Holdings Limited and its shareholders.
  • Scheme involves acquiring all issued share capital by Hasfarm Holdings Limited and Hasfarm Bidco Pty Ltd.
  • Shareholders to receive $2.155 cash per share, representing a premium to recent trading prices.
  • Scheme approved by requisite majorities of shareholders at the meeting.
  • Court approval required for the scheme to proceed.
  • No superior proposal has emerged since the scheme implementation agreement was signed.
  • Transaction costs estimated at $5 million, with $2.5 million non-recoverable if the scheme does not proceed.
  • Independent expert concluded the scheme is fair and reasonable, in the best interest of shareholders.
  • Lynch directors unanimously recommend voting in favor of the scheme.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.